These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 27444658)

  • 21. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
    Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
    J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    Golan T; Barenboim A; Lahat G; Nachmany I; Goykhman Y; Shacham-Shmueli E; Halpern N; Brazowski E; Geva R; Wolf I; Goldes Y; Ben-Haim M; Klausner JM; Lubezky N
    Ann Surg Oncol; 2020 Oct; 27(10):3963-3970. PubMed ID: 32314163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
    Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
    Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
    Polish A; Joseph NE; Marsh RW
    Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.
    van Veldhuisen E; Klompmaker S; Janssen QP; Hilal MA; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Conlon KC; Frigerio IM; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Keck T; Kleeff J; Klaiber U; Labori KJ; Lesurtel M; Malleo G; Marino MV; Molenaar IQ; Mortensen MB; Nikov A; Pagnanelli M; Pandé R; Pfeiffer P; Pietrasz D; Rangelova E; Roberts KJ; Cunha AS; Salvia R; Strobel O; Tarvainen T; Wilmink JW; Koerkamp BG; Besselink MG;
    Ann Surg Oncol; 2023 Mar; 30(3):1463-1473. PubMed ID: 36539580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
    Botta GP; Huynh TR; Spierling-Bagsic SR; Agelidis A; Schaffer R; Lin R; Sigal D
    Cancer Med; 2023 Apr; 12(7):7713-7723. PubMed ID: 36478411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
    Jones TS; Jones EL; McManus M; Shah R; Gajdos C
    JOP; 2013 May; 14(3):289-91. PubMed ID: 23669483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of borderline resectable pancreatic cancer.
    Cooper AB; Tzeng CW; Katz MH
    Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.